October 25 | 2023
KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)
Read more
October 11 | 2023
2cureX advances towards IVD-R compliance by securing a contract with a Notified Body
Read more
October 3 | 2023
2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).
Read more
August 30 | 2023
2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation
Read more
August 24 | 2023
2cureX publishes interim report for Q2 2023
Read more
July 5 | 2023
Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)
Read more
June 15 | 2023
2cureX Newsletter. Our colorectal cancer portfolio is on track – Pancreatic cancer is next.
Read more
May 25 | 2023
Kommuniké från årsstämma i 2cureX AB
Read more
May 25 | 2023
2cureX publishes interim report for the first quarter of 2023
Read more
May 11 | 2023
Positive IndiTreat® trial results published in highly recognized scientific journal.
Read more
April 27 | 2023
Kallelse till årsstämma i 2cureX AB (publ)
Read more
April 27 | 2023
Notice of annual general meeting of 2cureX AB (publ)
Read more
April 25 | 2023
2cureX’s CEO Fernando Andreu purchases shares in the company
Read more
April 20 | 2023
2cureX offentliggör årsredovisning för räkenskapsåret 2022
Read more
April 20 | 2023
2cureX publishes the annual report for the fiscal year 2022
Read more
April 12 | 2023
2cureX presents preliminary Q1 2023 commercial results.
Read more
April 12 | 2023
2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.
Read more
April 10 | 2023
Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)
Read more